期刊
NATURE MEDICINE
卷 17, 期 3, 页码 304-312出版社
NATURE PORTFOLIO
DOI: 10.1038/nm.2311
关键词
-
资金
- Dutch Cancer Society
- The Netherlands Organisation for Scientific Research
- European Research Council
- National Health and Medical Research Council of Australia
The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for cancer requires a parallel effort to characterize cancers at the molecular level to guide the choice of therapy for the individual patient. Here we review the genomic technologies that can be used to develop these drug response indicators, or biomarkers. We also discuss hurdles in their development and the implementation of biomarkers in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据